I agree with everything you have stated. Also besides the science of companies I also look at management. Was it bad timing they changed CFO's 2 weeks before the 10-k was due? yes it was , but the new guy has to go through an entire year's book in just under 2 weeks. Even though the other CFO went through it, the new guy has to sign his name off on that work. So he wants to make sure what he is signing is in good order nothing wrong with that.
In terms of management the last few months they have brought on board some good people. The new board of directors, management have come from good companies. Some of the big pharma the new employees for AMBS have come from Pharmacyclics, Johnson and Johnson, and Novartis. The CEO had to entice those big executives with either big money or good science to get them to come on aboard on a stock that trades at .08 cents on the OTC. Regardless these executives came on board and they see a change in research on alzheimer's disease with Lympro and MANF.
I guarantee there will be a partnership on Lympro because from what I understand the big pharmaceutical companies that fail Alzheimer's trials do so not because their compound doesn't work but 30% of the patients enrolled skew the data because they don't even have alzheimer's disease. With an accurate test "Lympro" it may be possible to get more accurate data on who really has Alzheimer's or not. So in closing I have bought my shares and I'm ready for a long term story that will continue to be played throughout many years.
News 
Market Data 
Discover 
